Paired box 9 (PAX9) is a transcription factor of the PAX family functioning as both a transcriptional activator and a repressor. At this stage it has been demonstrated that the PAX9 gene is a key gene in embryonic development, but its function in a variety of cancers is still unknown. PAX9 was found to be overexpressed in lung adenocarcinoma (LUAD) samples according to the TCGA database on the Bioinformatics website. At the same time, it was found that PAX9 expression was higher in lung cancer cell lines compared to normal lung epithelial cell lines by qRT-PCR and Western Blot. To investigate the role of PAX9 in LUAD, an A549 cell line with stable knockdown of PAX9 was constructed. It was demonstrated by EdU assay that PAX9 could promote the proliferation of A549 cells by promoting cell cycle changes. In parallel, wound healing assay and transwell assay were performed, and the results showed that knockdown of PAX9 significantly inhibited the migration and invasion ability of A549 cell line. Our results showed that in A549 cell lines, the higher expression of PAX9, the higher ability of proliferation, migration and invasion. Our study may provide new therapeutic ideas for the future treatment of LUAD.
Increasing evidence suggests that RHBDD2 is involved in the development and progression of a variety of tumors, but its role in colorectal adenocarcinoma (COAD) remains unclear. Therefore, the aim of our study was to investigate the exact role of RHBDD2 in COAD. The expression levels of RHBDD2 in COAD were analyzed based on The Cancer Genome Atlas (TCGA) database. Survival analysis of RHBDD2 in COAD was analyzed using the TCGA dataset. In addition, the functional role of RHBDD2 was detected by GO, KEGG, and immune infiltration analysis. The results showed that RHBDD2 was significantly upregulated in COAD samples. High RHBDD2 expression in COAD was significantly correlated with T, N, and M stages and pathological stage. Elevated RHBDD2 expression was unfavorable for overall survival (OS), progression-free interval (PFI), and disease-specific survival (DSS). Receiver operating characteristic (ROC) analysis showed that RHBDD2 may serve as a potential diagnostic biomarker for COAD patients. In addition, RHBDD2 was significantly correlated with the level of immune cell infiltration. The current study suggests that elevated RHBDD2 expression is closely associated with poor prognosis and immune cell infiltration in COAD, and may serve as a promising independent prognostic biomarker and potential therapeutic target.
Cervical cancer is a disease that develops from an abnormal proliferation of cervical tissue to a malignant tumor. The primary etiological factor in the development of cervical cancer is the infection with high-risk human papillomavirus (HPV), particularly the HPV types 16 and 18. Cholesterol is an essential component of cell membranes and an important substance for cell signaling. DHCR24, also known as 24-dehydrocholesterol reductase, is a gene that encodes a flavin adenine dinucleotide (FAD)-dependent oxidoreductase. DHCR24 is involved in cholesterol synthesis through the enzymes it encodes, which in turn affects lipid metabolism and various pathophysiological processes. Studies have demonstrated that variants in the DHCR24 gene can result in the rare syndrome of multiple tissue congenital anomalies. In this study, we employed informatics analysis to investigate the role of DHCR24 in the development and prognosis of cervical cancer. The transcriptional profiles of DHCR24 were evaluated in pan-cancer and cervical cancer, respectively, using the online website TIMER. We evaluated the overexpression of DHCR24 mRNA in cervical cancer and 18 other cancers. Gene set enrichment analysis (GSEA) demonstrated that DHCR24 is associated with cell cycle and tumor cell adhesion molecules. Furthermore, the expression of DHCR24 may be related to the proliferation and migration of cervical cancer cells, as well as the stem cell capacity of the tumor cells. To verify these findings, we constructed normal cervical cancer cells and DHCR24 knockdown cells and performed scratch and cell cloning experiments. Subsequently, the relationship between DHCR24 expression level and immune cell infiltration was analyzed using XIANTAO and TIMER tools. The findings indicated that the upregulation of DHCR24 was negatively correlated with the majority of immune infiltrating cells. The findings of this study indicate that DHCR24 may be associated with the progression of cervical cancer and may serve as a potential marker for the diagnosis of cervical cancer.
Numerous new cases of breast cancer are diagnosed among women each year, rendering breast cancer the most common and rapidly expanding form of cancer in females globally. NDUFAF6 encodes a protein that localizes to mitochondria and contains a predicted phytoene synthase domain. Mutations in NDUFAF6 are associated with complex I enzymatic deficiency. This study explored the role of NDUFAF6 in breast cancer development and prognosis using informatic analysis. Through the online website TIMER, we evaluated the transcription profile of NDUFAF6 across pan-cancer and breast cancer respectively. We investigated that NDUFAF6 mRNA was overexpressed in breast cancer and other 18 cancers. NDUFAF6 expression also related to the subtype, pathological stage and prognosis of breast cancer. The GSEA showed NDUFAF6 correlated with cell cycle and tumor cell adhesion molecules. NDUFAF6 expression may associate with the proliferation and migration ability of breast cancer cells. Subsequently, the association between the NDUFAF6 expression level and immune cell infiltration was analyzed using the XIANTAO and TIMER tools. The results revealed a negative correlation between NDUFAF6 and most immune infiltrating cells. This study indicated that NDUFAF6 may role in the progression of breast cancer and potentially been one of the markers for diagnosis.